Drug Database
Back to search

Poland· PL-100499451

Ubretid

A distigmine product containing distigmini bromidum, registered in Poland by Delfarma Sp. z o.o.. The same ATC class is registered in 7 of our 19 countries.

ATC N07AA03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedUbretidATCN07AA03REGISTER NO.PL-100499451PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about distigmini bromidumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Distigmine is registered in 7 of 19 countries.

Countries holding a registration under ATC N07AA03 (distigmine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 3 of them publish a price we can compare per daily dose
Search distigmine products by name

Distigmine · ATC N07AA03

7 / 19 countries

  • Czechiaprice
  • Finlandprice
  • Germany
  • Japan
  • Netherlands
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Distigmini bromidum
Manufacturer
Delfarma Sp. z o.o.
Country
Poland (PL)
ATC code
N07AA03
ATC class
Distigmine
Defined daily dose
5 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05909991549244
  • gtin
    05909991549251

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Distigmine in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All distigmine products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Czechia · Ubretid
  • Germany · Ubretid
  • Netherlands · Ubretid
  • Slovakia · Ubretid

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3e2060bf-e98c-422a-8ce9-20c12044e9c7
GET /v1/drugs/3e2060bf-e98c-422a-8ce9-20c12044e9c7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "5 mg",
  "packaging": "05909991549244 ¦ Rp ¦ 156896\n50 tabl.\n05909991549251 ¦ Rp ¦ 156897\n20 tabl.",
  "substance": "Distigmini bromidum 5 mg",
  "common_name": "Distigmini bromidum",
  "pl_product_id": "100499451",
  "pozwolenie_nr": "252/24",
  "auth_procedure": "IR",
  "authorisation_validity": "2029-06-25"
}
API referenceMCP serverPlans

See everything about distigmine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console